topic

621 A phase I study of autologous activated NK cells ± rhIL15 in children and young adults with refractory solid tumors
Julia Segal, Sabina Kaczanowska, Donna Bernstein, Nan Zhang, Anh Dinh, Robert Somerville, Steven Highfill, David Stroncek, Kevin Conlon, Thomas Waldmann, Rosa Nguyen, Melinda S Merchant, Crystal L Mackall, Rosandra N Kaplan

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A708; DOI: 10.1136/jitc-2023-SITC2023.0621
622 Immune phenotype and iFRET functional analysis are biomarkers of response to neoadjuvant intralesional therapy for high risk stage II melanoma
Amanda Kirane, Michael C Lowe, Mohammad Usman Ahmad, Saurabh Sharma, Mamatha Serasanambati, Allison B Warner, Chris Applebee, Elena Safrygina, Susan Swetter, Sunil Reddy, Emanual Maverakis, Banafshe Larijani

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A709; DOI: 10.1136/jitc-2023-SITC2023.0622
623 AI-designed personalized neoantigen vaccine, EVX-02, induces robust T-cell responses in melanoma patients
Daniela Kleine-Kohlbrecher, Nadia Viborg, Michail A Pavlidis, Mads Lausen, Thomas Trolle, Nikolas H Thuesen, Christian Garde, Anders Jespersen, Thomas S Jepsen, Britt W Lauenborg, Birgitte Rønø

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A710; DOI: 10.1136/jitc-2023-SITC2023.0623
624 Longitudinal scRNAseq profiling of PBMCs from melanoma patients treated with anti-CTLA4 or anti-PD1/CTLA4 combination elucidates mechanisms of immunotherapy resistance
Ana Lako, Sharmila Chamling Rai, Piali Mukherjee, Brendan O’Brien, Daniel Tenney, Sonia Dolfi, Rupal Bhatt, Benjamin Chen

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A711-A712; DOI: 10.1136/jitc-2023-SITC2023.0624
625 Immune priming IFx-Hu2.0 promotes antibody responses necessary for anti-PD1 responses in PD-1 refractory melanoma patients
Joseph Markowitz, Michael Shamblott, Andrew S Brohl, Amod A Sarnaik, Zeynep Eroglu, Nikhil I Khushalani, Christopher W Dukes, Alejandra Chamizo, Marina Bastawrous, Edward Garcia, Ashraf Delhawi, Pei-Ling Chen, Deanryan BDe Aquino, Vernon K Sondak, Ahmad A Tarhini, Youngchul Kim, Patricia Lawman, Shari Pilon-Thomas

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A713; DOI: 10.1136/jitc-2023-SITC2023.0625
626 Long-term outcomes of a randomized trial of two multipeptide melanoma vaccines (Mel39) suggests outcome differences based on participant sex
Emily K Ninmer, Craig L Slingluff

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A714-A715; DOI: 10.1136/jitc-2023-SITC2023.0626
627 The effect of LNS8801 in combination with pembrolizumab in patients with treatment-refractory cutaneous melanoma
Jordi Rodon, Marya Chaney, Justine Cohen, Tina Garyantes, Jessica Lin, Jeffrey Ishizuka, Alain Mita, Monica Mita, Carolyn Muller, Christopher Natale, Marlana Orloff, Kyriakos P Papadopoulos, Sapna Patel, Alexander Shoushtari

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A716; DOI: 10.1136/jitc-2023-SITC2023.0627
628 Circulatory plasma proteomic biomarkers combined with high-throughput proteomic screen of patient-derived organotypic tumor spheroids predict responses to immunotherapy in melanoma patients
Marijana Rucevic, Arnav Mehta, Russell W Jenkins, Amrita Kar, Angelina Cicerchia, Or-Yam Revach, Yi Sun, Ryan Park, Alexis Schneider, William Michaud, Benchun Miao, Gyulnara Kasumova, Michael Forster, Dennie Frederick, Michelle Kim, Ryan Sullivan, Keith Flaherty, Nir Hacohen, Genevieve M Boland

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A717; DOI: 10.1136/jitc-2023-SITC2023.0628
629 Neoadjuvant SEMA4D inhibitor pepinemab combination with nivolumab increases crosstalk between B cell and CD26^hi T cell in patients with resectable stage III melanoma
Ayana T Ruffin, Brian Olson, Crystal Mallow, Christine Reilly, Jacklyn Hammons, Jayden Kim, Brian Burns, Agnes Harutyunyan, Elizabeth Evans, Terrence Fisher, Maurice Zauderer, Keith A Delman, Melinda Yushak, Ali Mokhtari, Douglas Parker, Ragini Kudchadkar, Chrystal M Paulos, Gregory B Lesinski, Michael C Lowe

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A718; DOI: 10.1136/jitc-2023-SITC2023.0629
630 EO2401, a new peptide immunotherapy against cancer, in combination with nivolumab, induces a strong and durable immune response in patients from the EOADR1–19/SPENCER study
Lucie Aubergeon, Eric Baudin, Alfredo Berruti, Salvatore Grisanti, CWillemien Menke-vander Houven van Oordt, Harm Haak, Martin Fassnacht, Jaume Capdevila, Vivek Subbiah, Camilo Jimenez, Christelle de la Fouchardière, Dan Granberg, Matthias Kroiss, Gedske Daugaard, Hélène Toussaint, Joao Gamelas Magalhaes, Jennifer Martinez, Camille Belyn, Jerome Kervevan, Chloé Ventujol, Christophe Bonny, Jean-Michel Paillarse, Laurent Chene

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A719; DOI: 10.1136/jitc-2023-SITC2023.0630

Main menu

topic

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

topic

Pages